2010-2011年岐阜县、爱知县肺炎链球菌分离株抗菌药物敏感性监测[j]。

The Japanese journal of antibiotics Pub Date : 2013-10-01
Maki Eto, Shingo Mizunaga, Yoshiko Fukuda, Nobuhiko Nomura, Yoko Matsukawa, Junichi Mitsuyama, Shigenori Matsubara, Kazukiyo Yamaoka, Kunitomo Watanabe, Yuko Asano, Hiroyuki Suematsu, Haruki Sawamura, Hikonori Hashido, Yuka Yamagishi, Hiroshige Mikamo
{"title":"2010-2011年岐阜县、爱知县肺炎链球菌分离株抗菌药物敏感性监测[j]。","authors":"Maki Eto,&nbsp;Shingo Mizunaga,&nbsp;Yoshiko Fukuda,&nbsp;Nobuhiko Nomura,&nbsp;Yoko Matsukawa,&nbsp;Junichi Mitsuyama,&nbsp;Shigenori Matsubara,&nbsp;Kazukiyo Yamaoka,&nbsp;Kunitomo Watanabe,&nbsp;Yuko Asano,&nbsp;Hiroyuki Suematsu,&nbsp;Haruki Sawamura,&nbsp;Hikonori Hashido,&nbsp;Yuka Yamagishi,&nbsp;Hiroshige Mikamo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We investigated genotype of penicillin-binding protein (PBP) genes and macrolide resistant genes, the serotypes and the susceptibility to antibacterial agents against 258 strains of Streptococcus pneumoniae isolated from medical facilities in Gifu and Aichi prefectures between January 2010 and March 2011. These results were compared with those against 377 strains of S. pneumoniae isolated in 2008-2009. The number of genotype penicillin-susceptible S. pneumoniae (gPSSP) with 3 normal PBP genes, genotype penicillin-intermediate S. pneumoniae (gPISP) with 1 or 2 normal PBP genes and genotype penicillin-resistant S. pneumoniae (gPRSP) with 3 abnormal genes was 11 (4.3%), 135 (52.3%) and 112 (43.4%) strains, respectively. The isolates with no macrolide-resistant gene, only mefA, only ermB, and both mefA and ermB were 17 (6.6%), 65 (25.2%), 143 (55.4%) and 33 (12.8%). The prevalent pneumococcal serotypes isolated from children were type 19F (18.2%), following by type 6A and 15 (11.7%). The potential coverage of pneumococcal conjugate vaccine (PCV7) was 43.8%. The prevalent pneumococcal serotypes isolated from adults were high in order of type 19F (12.8%), type 6A, 3 and 11 (10.3%), excepting non-typable strains (17.9%), and from elderly persons were type 6B (23.2%) and type 3 (13.4%). The MIC90 of each antibacterial agents was as follows; 0.0625 microg/mL for garenoxacin, 0.125 microg/mL for panipenem, 0.25 microg/mL for imipenem, doripenem, tosufloxacin, 0.5 microg/mL for cefditoren, meropenem, moxifloxacin, 1 microg/mL for amoxicillin, clavulanic acid/amoxicillin, cefteram, cefcapene, ceftriaxone, 2 microg/mL for benzylpenicillin, piperacillin, tazobactam/ piperacillin, pazufloxacin, levofloxacin, 4 microg/mL for cefdinir, flomoxef, 16 microg/mL for minocycline, > 64 microg/mL for clarithromycin, azithromycin and these MIC90s were about the same as those in 2008-2009.</p>","PeriodicalId":22536,"journal":{"name":"The Japanese journal of antibiotics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefecture (2010-2011)].\",\"authors\":\"Maki Eto,&nbsp;Shingo Mizunaga,&nbsp;Yoshiko Fukuda,&nbsp;Nobuhiko Nomura,&nbsp;Yoko Matsukawa,&nbsp;Junichi Mitsuyama,&nbsp;Shigenori Matsubara,&nbsp;Kazukiyo Yamaoka,&nbsp;Kunitomo Watanabe,&nbsp;Yuko Asano,&nbsp;Hiroyuki Suematsu,&nbsp;Haruki Sawamura,&nbsp;Hikonori Hashido,&nbsp;Yuka Yamagishi,&nbsp;Hiroshige Mikamo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We investigated genotype of penicillin-binding protein (PBP) genes and macrolide resistant genes, the serotypes and the susceptibility to antibacterial agents against 258 strains of Streptococcus pneumoniae isolated from medical facilities in Gifu and Aichi prefectures between January 2010 and March 2011. These results were compared with those against 377 strains of S. pneumoniae isolated in 2008-2009. The number of genotype penicillin-susceptible S. pneumoniae (gPSSP) with 3 normal PBP genes, genotype penicillin-intermediate S. pneumoniae (gPISP) with 1 or 2 normal PBP genes and genotype penicillin-resistant S. pneumoniae (gPRSP) with 3 abnormal genes was 11 (4.3%), 135 (52.3%) and 112 (43.4%) strains, respectively. The isolates with no macrolide-resistant gene, only mefA, only ermB, and both mefA and ermB were 17 (6.6%), 65 (25.2%), 143 (55.4%) and 33 (12.8%). The prevalent pneumococcal serotypes isolated from children were type 19F (18.2%), following by type 6A and 15 (11.7%). The potential coverage of pneumococcal conjugate vaccine (PCV7) was 43.8%. The prevalent pneumococcal serotypes isolated from adults were high in order of type 19F (12.8%), type 6A, 3 and 11 (10.3%), excepting non-typable strains (17.9%), and from elderly persons were type 6B (23.2%) and type 3 (13.4%). The MIC90 of each antibacterial agents was as follows; 0.0625 microg/mL for garenoxacin, 0.125 microg/mL for panipenem, 0.25 microg/mL for imipenem, doripenem, tosufloxacin, 0.5 microg/mL for cefditoren, meropenem, moxifloxacin, 1 microg/mL for amoxicillin, clavulanic acid/amoxicillin, cefteram, cefcapene, ceftriaxone, 2 microg/mL for benzylpenicillin, piperacillin, tazobactam/ piperacillin, pazufloxacin, levofloxacin, 4 microg/mL for cefdinir, flomoxef, 16 microg/mL for minocycline, > 64 microg/mL for clarithromycin, azithromycin and these MIC90s were about the same as those in 2008-2009.</p>\",\"PeriodicalId\":22536,\"journal\":{\"name\":\"The Japanese journal of antibiotics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Japanese journal of antibiotics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Japanese journal of antibiotics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

对2010年1月至2011年3月从岐阜县和爱知县医疗机构分离的258株肺炎链球菌进行了青霉素结合蛋白(PBP)基因型和大环内酯类耐药基因型、血清型及对抗菌药物的敏感性研究。这些结果与2008-2009年分离的377株肺炎链球菌的结果进行了比较。含有3个PBP基因正常的青霉素敏感型肺炎链球菌(gPSSP)、含有1或2个PBP基因正常的青霉素中间型肺炎链球菌(gPISP)和含有3个基因异常的青霉素耐药型肺炎链球菌(gPRSP)分别为11株(4.3%)、135株(52.3%)和112株(43.4%)。无大环内酯耐药基因的分离株分别为17株(6.6%)、65株(25.2%)、143株(55.4%)和33株(12.8%)。从儿童中分离出的流行肺炎球菌血清型为19F型(18.2%),其次是6A型和15型(11.7%)。肺炎球菌结合疫苗(PCV7)的潜在覆盖率为43.8%。成人分离的肺炎球菌流行血清型依次为19F型(12.8%)、6A型、3型和11型(10.3%)(除不可分型株(17.9%)外),老年人分离的肺炎球菌流行血清型依次为6B型(23.2%)和3型(13.4%)。各抗菌药的MIC90为:加宁诺昔星0.0625微克/毫升,帕尼培南0.125微克/毫升,亚胺培南、多利培南、托苏沙星0.25微克/毫升,头孢地托伦、美罗培南、莫西沙星0.5微克/毫升,阿莫西林、克拉维酸/阿莫西林、头孢特仑、头孢capene、头孢曲松1微克/毫升,青霉素、哌拉西林、他唑巴坦/哌拉西林、帕唑沙星、左氧氟沙星2微克/毫升,头孢地尼、氟莫西夫4微克/毫升,米诺环素16微克/毫升,克拉霉素> 64微克/毫升,这些mic90与2008-2009年基本相同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefecture (2010-2011)].

We investigated genotype of penicillin-binding protein (PBP) genes and macrolide resistant genes, the serotypes and the susceptibility to antibacterial agents against 258 strains of Streptococcus pneumoniae isolated from medical facilities in Gifu and Aichi prefectures between January 2010 and March 2011. These results were compared with those against 377 strains of S. pneumoniae isolated in 2008-2009. The number of genotype penicillin-susceptible S. pneumoniae (gPSSP) with 3 normal PBP genes, genotype penicillin-intermediate S. pneumoniae (gPISP) with 1 or 2 normal PBP genes and genotype penicillin-resistant S. pneumoniae (gPRSP) with 3 abnormal genes was 11 (4.3%), 135 (52.3%) and 112 (43.4%) strains, respectively. The isolates with no macrolide-resistant gene, only mefA, only ermB, and both mefA and ermB were 17 (6.6%), 65 (25.2%), 143 (55.4%) and 33 (12.8%). The prevalent pneumococcal serotypes isolated from children were type 19F (18.2%), following by type 6A and 15 (11.7%). The potential coverage of pneumococcal conjugate vaccine (PCV7) was 43.8%. The prevalent pneumococcal serotypes isolated from adults were high in order of type 19F (12.8%), type 6A, 3 and 11 (10.3%), excepting non-typable strains (17.9%), and from elderly persons were type 6B (23.2%) and type 3 (13.4%). The MIC90 of each antibacterial agents was as follows; 0.0625 microg/mL for garenoxacin, 0.125 microg/mL for panipenem, 0.25 microg/mL for imipenem, doripenem, tosufloxacin, 0.5 microg/mL for cefditoren, meropenem, moxifloxacin, 1 microg/mL for amoxicillin, clavulanic acid/amoxicillin, cefteram, cefcapene, ceftriaxone, 2 microg/mL for benzylpenicillin, piperacillin, tazobactam/ piperacillin, pazufloxacin, levofloxacin, 4 microg/mL for cefdinir, flomoxef, 16 microg/mL for minocycline, > 64 microg/mL for clarithromycin, azithromycin and these MIC90s were about the same as those in 2008-2009.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Carumonam]. [Cefroxadine]. Importance of prevention in pneumonia in elderly -Attempted use of macrolide therapy. High efficiency method of detection and isolation of neuraminidase inhibitor resistant influenza viruses by fluorescence sialidase imaging. The change of susceptibility of Streptococcus pneumoniae strains isolated from pediatric patients at Asahikawa Kosei Hospital between 2011 and 2015.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1